GlassScriptPhysician profile
Taylor C Fitzpatrick
NPI 1376263186
$1,624.56
in general payments reported to CMS, 2019-2025
17 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.02 · 2023: $492 · 2024: $526 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.30 | 2023-2025 | |
| Exact Sciences Corporation | $160.92 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $159.71 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $112.20 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $88.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.92 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $75.37 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $52.86 | 2024-2025 | Sunosi |
| Esperion Therapeutics, INC. | $39.77 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $35.57 | 2022-2025 | Gardasil 9, Vaqta, Rotateq |
| Corcept Therapeutics | $34.21 | 2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $29.89 | 2024 | Trintellix |
| Ultragenyx Pharmaceutical INC. | $27.82 | 2023 | |
| Globus Medical, INC. | $25.49 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $22.93 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.60 | 2023 | Otezla, Repatha |
| Pharmacosmos Therapeutics INC. | $16.69 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.